Related Experiment Video
Updated: Jul 21, 2026
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Etanercept in the treatment of macrophage activation syndrome
S Prahalad1, K E Bove, D Dickens
1Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Ohio 45229-3039, USA.
Abstract:
Macrophage activation syndrome (MAS), a recognized complication of systemic juvenile rheumatoid arthritis (sJRA), has been associated with significant morbidity and mortality. Dysregulation of macrophage-lymphocyte interactions leading to uncontrolled proliferation of highly activated macrophages and massive release of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) appears to be central to the pathogenesis of this syndrome. Until now the mainstay of therapy has been corticosteroids and cyclosporin A. We describe a patient with MAS and sJRA successfully treated with the anti-TNF agent etanercept. The outcome in this patient suggests etanercept might be an effective therapeutic agent in MAS.
Insights
Macrophage activation syndrome (MAS), a complication of systemic juvenile rheumatoid arthritis (sJRA), can be serious. Etanercept, an anti-TNF agent, shows promise in treating MAS, offering a potential new therapy option.
Area of Science:
- Rheumatology
- Immunology
- Pediatrics
Background:
- Macrophage activation syndrome (MAS) is a severe complication of systemic juvenile rheumatoid arthritis (sJRA).
- MAS pathogenesis involves dysregulated macrophage-lymphocyte interactions and excessive pro-inflammatory cytokine release, including tumor necrosis factor-alpha (TNF-alpha).
- Current treatments for MAS primarily rely on corticosteroids and cyclosporin A.
Observation:
- A case study of a patient with MAS and sJRA is presented.
- This patient was treated with etanercept, a biologic agent targeting TNF-alpha.
Findings:
- The patient with MAS and sJRA experienced a successful outcome following treatment with etanercept.
- This suggests etanercept may be an effective therapeutic option for MAS.
Implications:
- Etanercept offers a potential novel therapeutic strategy for managing MAS in patients with sJRA.
- Further research into anti-TNF agents for MAS is warranted.
- This case highlights the importance of exploring targeted therapies for complex autoimmune conditions.
